Page last updated: 2024-12-09

phenylthiourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phenylthiourea: Phenylthiourea is a THIOUREA derivative containing a phenyl ring. Depending on their genetic makeup, humans can find it either bitter-tasting or tasteless. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-phenylthiourea : A member of the class of thioureas that is thiourea in which one of the hydrogens is replaced by a phenyl group. Depending on their genetic makeup, humans find it either very bitter-tasting or tasteless. This unusual property resulted in N-phenylthiourea being used in paternity testing prior to the advent of DNA testing. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID676454
CHEMBL ID263376
CHEBI ID46261
SCHEMBL ID42753
MeSH IDM0016577

Synonyms (87)

Synonym
AC-13462
EN300-18229
phenyl-thiourea
urea, 1-phenyl-2-thio-
1-phenylthiourea
.alpha.-phenylthiourea
1-phenyl-2-thiourea
n-phenylthiourea
nsc5779
u 6324
nsc-5779
wln: suyzmr
usaf ek-1569
phenylthiourea
phenylthiocarbamide
thiourea, phenyl-
nci-c02017
103-85-5
TIMTEC1_004784
2-thiourea, 1-phenyl-
URS ,
NCGC00090967-01
NCGC00090967-02
nsc 5779
rcra waste no. p093
rcra waste number p093
hsdb 4105
ai3-07549
ccris 514
einecs 203-151-2
fenylthiomocovina [czech]
PTC ,
inchi=1/c7h8n2s/c8-7(10)9-6-4-2-1-3-5-6/h1-5h,(h3,8,9,10
alpha-phenylthiourea
monophenyl thiourea
phenyl-2-thiourea
DB03694
1BUG
NCGC00090967-03
STK398097
n-phenylthiourea, >=98%
HMS1547J10
bdbm50240041
n-phenyl-thiourea
chebi:46261 ,
CHEMBL263376 ,
AKOS000266872
F3143-0088
P0237
A800823
NCGC00090967-04
thiourea, n-phenyl-
6f82c6q54c ,
fenylthiomocovina
unii-6f82c6q54c
dtxcid801134
NCGC00256507-01
cas-103-85-5
dtxsid9021134 ,
tox21_302998
tox21_201682
NCGC00259231-01
BBL013021
FT-0608239
phnhcsnh2
phnhc(s)nh2
phnhc(=s)nh2
n-phenylthiourea [mi]
1-phenyl-2-thiourea [hsdb]
SCHEMBL42753
n-phenylisothiourea
phenyl thiourea
n'-phenyl-thiourea
mfcd00004933
VU0510645-1
J-001049
n-phenylthiourea, 97%
n-phenylthiourea, pestanal(r), analytical standard
n-phenylthiourea, grade ii, >=90% (hplc)
phenyl 2-thiourea
Q411216
phenylthioharnstoff
AMY15530
MS-20376
CS-0015071
gtpl12496
Z57474172

Research Excerpts

Overview

Phenylthiourea (PTU) is a well-known inhibitor of tyrosinase and melanin synthesis. PTU is known to interact with sweet potato catechol oxidase.

ExcerptReferenceRelevance
"Phenylthiourea (PTU) is a well-known inhibitor of tyrosinase and melanin synthesis and is known to interact with sweet potato catechol oxidase, an enzyme possessing copper binding domain homology to tyrosinase."( Degradation of tyrosinase induced by phenylthiourea occurs following Golgi maturation.
Hall, AM; Orlow, SJ, 2005
)
1.32

Toxicity

ExcerptReferenceRelevance
"The rationale for melanoma specific dihydroxybenzene containing antitumor agents is based in part upon the ability of the enzyme tyrosinase to oxidize these pro drugs to toxic intermediates."( Effects of tyrosinase activity on the cytotoxicity of 3,4-dihydroxybenzylamine and buthionine sulfoximine in human melanoma cells.
Fitzgerald, GB; Prezioso, JA; Wick, MM,
)
0.13
" We investigated this newly discovered effect of PTU and its analogues in relation to the toxic effects of Cu ion."( Phenylthiourea enhances Cu cytotoxicity in cell cultures: its mode of action.
Eguchi, G; Masuda, A, 1984
)
1.71
" Based on the hazard ratio (the ratio between the field-recommended dose and the LD(50) for the beneficial), diafenthiuron was found to be slightly to moderately toxic to bees."( Toxicity of diafenthiuron to honey bees in laboratory, semi-field and field conditions.
Chandrasekaran, S; Kuttalam, S; Preetha, G; Stanley, J, 2010
)
0.36
" Isoxyl microparticles and controls in concentrations up to 100microg/ml were not toxic to macrophages."( Isoxyl particles for pulmonary delivery: In vitro cytotoxicity and potency.
Hickey, AJ; Wang, C, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" Tolerance studies, conducted in sheep of various types under several management systems, in which thiophanate was given orally at recommended dosage (50 to 100 mg/kg), or multiples thereof, in single or repeated doses showed that treatment was in all cases well tolerated."( Field trials in sheep with the anthelmintic thiophanate.
Baines, DM; Colegrave, AJ, 1977
)
0.26
"Thiophanate, administered at a dosage of 50 mg per kg to artifically infected pigs, removed 96 to 99 per cent of adult Oesophagostomum spp, Hyostrongylus rubidus and Trichuris suis."( Experimental and field studies with thiophanate in pigs.
Baines, DM; Dalton, SE; Eichler, DA, 1976
)
0.26
" Dose-response curves were obtained and concentrations in micrograms/ml required to give 90% inhibition of colony formation (IC90) were calculated."( Structure-activity relationships defining the cytotoxicity of catechol analogues against human malignant melanoma.
Driscoll, JS; Hildebrand-Zanki, SU; Kern, DH; Shoemaker, RH, 1988
)
0.27
" The area under the blood level versus time curve of mebendazole, in rats dosed with the prodrug, is more than twice that obtained after dosing rats with an equimolar amount of mebendazole."( 4-Amino-3-(3'-methoxycarbonyl-2'-thioureido)benzophenone, a prodrug of mebendazole.
Dawson, M; Watson, TR,
)
0.13
"Bioassays were conducted in 2001 and 2002 to estimate toxicities and dose-response relationships of 24 Bemisica tabaci Gennadius populations to pyriproxifen, acemitaprid, and diafenthiuron."( Field efficacy and baseline toxicities of pyriproxifen, acetamiprid, and diafenthiuron against Bemisia tabaci Gennadius (Homoptera: Aleyrodidae) in Burkina Faso (West Africa).
Otoidobiga, LC; Stewart, RK; Vincent, LC, 2003
)
0.32
" Neither the experimentally derived dose-response relationships for chemicals commonly used in the mounting of live fish larvae, nor their effect on the stress of the animal, are currently available in the research literature."( Dose-dependent effects of chemical immobilization on the heart rate of embryonic zebrafish.
Craig, MP; Gilday, SD; Hove, JR, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 1.14.18.1 (tyrosinase) inhibitorAny EC 1.14.18.* (oxidoreductase acting on paired donors, miscellaneous compound as one donor, incorporating 1 atom of oxygen) inhibitor that interferes with the action of tyrosinase (monophenol monooxygenase), EC 1.14.18.1, an enzyme that catalyses the oxidation of phenols (such as tyrosine) and is widespread in plants and animals.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
thioureasCompounds of general formula RR'NC(=S)NR''R'''.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
aurone biosynthesis019
betacyanin biosynthesis124
superpathway of betalain biosynthesis252

Protein Targets (35)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID886
LuciferasePhotinus pyralis (common eastern firefly)Potency90.89140.007215.758889.3584AID1224835
interleukin 8Homo sapiens (human)Potency74.97800.047349.480674.9780AID651758
pregnane X receptorRattus norvegicus (Norway rat)Potency39.81070.025127.9203501.1870AID651751
RAR-related orphan receptor gammaMus musculus (house mouse)Potency26.60330.006038.004119,952.5996AID1159521; AID1159523
AR proteinHomo sapiens (human)Potency19.64610.000221.22318,912.5098AID1259243
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency5.01190.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency22.04330.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency6.97070.001022.650876.6163AID1224838; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency5.64980.000214.376460.0339AID588532
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency30.42450.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency7.89280.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency45.32390.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401
farnesoid X nuclear receptorHomo sapiens (human)Potency0.00630.375827.485161.6524AID588527
pregnane X nuclear receptorHomo sapiens (human)Potency56.12260.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency48.17020.000229.305416,493.5996AID1259244; AID743079
activating transcription factor 6Homo sapiens (human)Potency62.69470.143427.612159.8106AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency17.66980.057821.109761.2679AID1159526
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency0.03980.316212.443531.6228AID924
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency36.11190.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency47.30790.000627.21521,122.0200AID651741
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency27.75090.001557.789015,848.9004AID1259244
Integrin beta-3Homo sapiens (human)Potency0.03980.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency0.03980.316211.415731.6228AID924
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency27.75090.001551.739315,848.9004AID1259244
Nuclear receptor ROR-gammaHomo sapiens (human)Potency4.30800.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, PROTEIN (CATECHOL OXIDASE)Ipomoea batatas (sweet potato)IC50 (µMol)43.000043.000043.000043.0000AID977608
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)1.53330.03403.987110.0000AID1265266; AID331282; AID626570
Polyphenol oxidase 2Agaricus bisporusKi0.30000.00063.28838.8900AID1265267
TyrosinaseMus musculus (house mouse)IC50 (µMol)1.80000.03002.21045.2300AID494974
TyrosinaseHomo sapiens (human)IC50 (µMol)1.80000.02304.459310.0000AID457969
TyrosinaseHomo sapiens (human)Ki1.70001.70004.73339.1000AID1717729
Succinyl-diaminopimelate desuccinylaseHaemophilus influenzae Rd KW20IC50 (µMol)100.00003.30003.30003.3000AID467024
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Taste receptor type 2 member 38Homo sapiens (human)EC50 (µMol)2.00000.00491.36102.3000AID1619468
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Taste receptor type 2 member 38Homo sapiens (human)Activity0.30000.15003.256310.0000AID1619467
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (96)

Processvia Protein(s)Taxonomy
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
melanin biosynthetic process from tyrosineTyrosinaseHomo sapiens (human)
eye pigment biosynthetic processTyrosinaseHomo sapiens (human)
visual perceptionTyrosinaseHomo sapiens (human)
cell population proliferationTyrosinaseHomo sapiens (human)
response to UVTyrosinaseHomo sapiens (human)
response to blue lightTyrosinaseHomo sapiens (human)
response to vitamin DTyrosinaseHomo sapiens (human)
melanin biosynthetic processTyrosinaseHomo sapiens (human)
thymus developmentTyrosinaseHomo sapiens (human)
response to cAMPTyrosinaseHomo sapiens (human)
pigmentationTyrosinaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 38Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 38Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (35)

Processvia Protein(s)Taxonomy
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
tyrosinase activityTyrosinaseHomo sapiens (human)
copper ion bindingTyrosinaseHomo sapiens (human)
protein bindingTyrosinaseHomo sapiens (human)
identical protein bindingTyrosinaseHomo sapiens (human)
protein homodimerization activityTyrosinaseHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 38Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 38Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (39)

Processvia Protein(s)Taxonomy
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
cytoplasmTyrosinaseHomo sapiens (human)
lysosomeTyrosinaseHomo sapiens (human)
Golgi-associated vesicleTyrosinaseHomo sapiens (human)
melanosome membraneTyrosinaseHomo sapiens (human)
melanosomeTyrosinaseHomo sapiens (human)
intracellular membrane-bounded organelleTyrosinaseHomo sapiens (human)
perinuclear region of cytoplasmTyrosinaseHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneTaste receptor type 2 member 38Homo sapiens (human)
membraneTaste receptor type 2 member 38Homo sapiens (human)
membraneTaste receptor type 2 member 38Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID331282Inhibition of mushroom tyrosinase2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation.
AID626569Inhibition of mushroom tyrosinase activity using L-tyrosine as substrate at 10 uM by spectrometric analysis2011Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22
Structural requirement of phenylthiourea analogs for their inhibitory activity of melanogenesis and tyrosinase.
AID1428457Inhibition of Acyrthosiphon pisum phenoloxidase using L-DOPA as substrate preincubated for 5 mins followed by substrate addition measured after 120 to 240 mins by spectrophotometric method2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Antioxidant Flavonols and Phenolic Compounds from Atraphaxis frutescens and Their Inhibitory Activities against Insect Phenoloxidase and Mushroom Tyrosinase.
AID331283Inhibition of melanin production in mouse B16 cells at 100 uM2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation.
AID480029Inhibition of melanogenesis in mouse B16 cells at 10 uM2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Structural requirement(s) of N-phenylthioureas and benzaldehyde thiosemicarbazones as inhibitors of melanogenesis in melanoma B 16 cells.
AID497308Cytotoxicity against mouse Melan-a cells assessed as cell viability at 30 uM2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Identification of a potent and noncytotoxic inhibitor of melanin production.
AID1717736Inhibition of melanogenesis in human SKMEL-188 cells assessed as IL2-activated peripheral blood lymphocyte-mediated cytotoxicity preincubated for 3 days followed by IL2-activated PBL addition and measured after 4 hrs by Cytotox96 nonradioactive cytotoxici2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Advances in the Design of Genuine Human Tyrosinase Inhibitors for Targeting Melanogenesis and Related Pigmentations.
AID494974Inhibition of tyrosinase in alpha-MSH-induced mouse B16 cells2010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Refinement of the pharmacophore of 3,4-dihydroquinazoline-2(1H)-thiones for their anti-melanogenesis activity.
AID497307Depigmentation effect in mouse Melan-a cells assessed as difference between cell viability and melanin content at 30 uM2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Identification of a potent and noncytotoxic inhibitor of melanin production.
AID1428458Inhibition of mushroom tyrosinase using L-DOPA as substrate preincubated for 5 mins followed by substrate addition measured for 10 mins by spectrophotometric method2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Antioxidant Flavonols and Phenolic Compounds from Atraphaxis frutescens and Their Inhibitory Activities against Insect Phenoloxidase and Mushroom Tyrosinase.
AID492070Inhibition of tyrosinase in human HEMn-MP assessed as reduction of melanin level at 100 uM after 2 days by spectrophotometric analysis2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
(-)-N-Formylanonaine from Michelia alba as a human tyrosinase inhibitor and antioxidant.
AID1866764Inhibition of melanogenesis in zebra fish embryos assessed as decrease in melanin granule density at 10 to 50 uM measured upto 6 days by inverted microscope analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Selaginellin Inhibits Melanogenesis via the MAPK Signaling Pathway.
AID1428456Antioxidant activity assessed as DPPH radical scavenging activity incubated for 30 mins2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Antioxidant Flavonols and Phenolic Compounds from Atraphaxis frutescens and Their Inhibitory Activities against Insect Phenoloxidase and Mushroom Tyrosinase.
AID1265266Inhibition of mushroom tyrosinase using L-tyrosine as substrate2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1134600Octanol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID1265269Binding affinity to mushroom tyrosinase assessed as fluorescence quenching2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265272Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction of melanin production at 20 uM relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265267Competitive inhibition of mushroom tyrosinase using L-tyrosine as substrate by Lineweaver-Burk plots analysis2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265271Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction of melanin production at 10 uM relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1721838Inhibition of Pseudomonas aeruginosa PvdP tyrosinase2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Development of phenylthiourea derivatives as allosteric inhibitors of pyoverdine maturation enzyme PvdP tyrosinase.
AID1265273Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction of melanin production at 50 uM relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1717729Uncompetitive inhibition of recombinant human tyrosinase expressed in baculovirus infected sf9 cells using L-DOPA as substrate by double-reciprocal plot analysis2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Advances in the Design of Genuine Human Tyrosinase Inhibitors for Targeting Melanogenesis and Related Pigmentations.
AID494973Antimelanogenic activity in mouse B16 cells assessed as inhibition of alpha-MSH-induced melanogenesis at 100 uM2010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Refinement of the pharmacophore of 3,4-dihydroquinazoline-2(1H)-thiones for their anti-melanogenesis activity.
AID1265270Cytotoxicity against mouse B16F10 cells assessed as cell survival at 50 uM after 48 hrs by MTT assay2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID467024Inhibition of Haemophilus influenzae recombinant DapE2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Inhibitors of bacterial N-succinyl-L,L-diaminopimelic acid desuccinylase (DapE) and demonstration of in vitro antimicrobial activity.
AID626570Inhibition of mushroom tyrosinase activity using L-tyrosine as substrate by spectrometric analysis2011Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22
Structural requirement of phenylthiourea analogs for their inhibitory activity of melanogenesis and tyrosinase.
AID457969Inhibition of tyrosinase2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Evaluation of 3,4-dihydroquinazoline-2(1H)-thiones as inhibitors of alpha-MSH-induced melanin production in melanoma B16 cells.
AID1134599CHCl3-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID480030Inhibition of melanogenesis in mouse B16 cells2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Structural requirement(s) of N-phenylthioureas and benzaldehyde thiosemicarbazones as inhibitors of melanogenesis in melanoma B 16 cells.
AID1265274Inhibition of tyrosinase in mouse B16F10 cell lysates using DOPA as substrate relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID457971Inhibition of alpha-MSH-induced melanin production in mouse B16 cells at 100 uM after 72 hrs2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Evaluation of 3,4-dihydroquinazoline-2(1H)-thiones as inhibitors of alpha-MSH-induced melanin production in melanoma B16 cells.
AID1811Experimentally measured binding affinity data derived from PDB1998Nature structural biology, Dec, Volume: 5, Issue:12
Crystal structure of a plant catechol oxidase containing a dicopper center.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB1998Nature structural biology, Dec, Volume: 5, Issue:12
Crystal structure of a plant catechol oxidase containing a dicopper center.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (915)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990613 (66.99)18.7374
1990's61 (6.67)18.2507
2000's97 (10.60)29.6817
2010's121 (13.22)24.3611
2020's23 (2.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.12 (24.57)
Research Supply Index6.93 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index56.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials26 (2.60%)5.53%
Reviews41 (4.10%)6.00%
Case Studies4 (0.40%)4.05%
Observational1 (0.10%)0.25%
Other928 (92.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]